Kura Oncology, Inc. filed a Form 8-K on September 9, 2026, disclosing the formation of a wholly owned subsidiary, Caspian Therapeutics, Inc., and the completion of a $50.0 million Series A preferred stock financing for that subsidiary on September 8, 2026.
Key Highlights
- $50.0 million raised: Caspian Therapeutics completed the sale and issuance of $50.0 million of shares of its Series A preferred stock in a private financing on September 8, 2026.
- Kura invested $4.3 million: The company participated in the Series A Financing by investing $4.3 million.
- ~49.2% ownership retained: Immediately following the financing, Kura's common stock and Series A preferred stock of Caspian comprised approximately 49.2% of Caspian's outstanding capital stock.
- Contribution and License Agreement: Kura contributed certain rights to next-generation menin inhibitors, including compound KO-7246, plus related intellectual property and assets to Caspian in exchange for Caspian common stock and a reimbursement payment of up to $1.5 million.
- Caspian's focus: Caspian is solely responsible for development, regulatory, and commercialization activities for products in the field of diabetes and other cardiometabolic diseases, according to the filing.
- Intercompany Services Agreement signed: Kura agreed to provide research and development, general administrative, and other services to Caspian for service fees, with an initial term through the first anniversary of the effective date.
Kura Oncology Spins Out Caspian Therapeutics With Menin Inhibitor Assets
According to the filing, Kura Oncology, Inc. (NASDAQ:KURA) formed Caspian Therapeutics, Inc. as a wholly owned subsidiary to pursue next-generation menin inhibitors for the treatment of diabetes and other cardiometabolic diseases. On September 8, 2026, Caspian closed a $50.0 million Series A preferred stock financing in a private transaction, with Kura contributing $4.3 million of that total. After the financing closed, the company's combined common stock and Series A preferred stock holdings represented approximately 49.2% of Caspian's outstanding capital stock.
Concurrent with the financing, the company entered into a Contribution and License Agreement with Caspian on September 8, 2026. Under that agreement, Kura contributed rights to next-generation menin inhibitors for the cardiometabolic field, including the compound internally designated KO-7246, along with corresponding intellectual property and other assets. In return, Kura received Caspian common stock and is eligible to receive a one-time reimbursement of up to $1.5 million for costs incurred maintaining those assets prior to closing. The filing states that Kura also granted Caspian non-exclusive, worldwide, royalty-free, fully paid-up, irrevocable, and perpetual licenses under certain of Kura's patents and data relating to ziftomenib for use in the cardiometabolic field. Reciprocally, Caspian granted Kura a similar license under the contributed patents and know-how for any research and development purpose.
The filing further discloses that both parties entered into an Intercompany Services Agreement on September 8, 2026, under which Kura agreed to provide Caspian with research and development services, general administrative services, and other mutually agreed services in exchange for service fees. The agreement's initial term runs through its first anniversary and renews automatically for successive one-year terms, unless either party provides at least 90 days' notice of non-renewal. Caspian may terminate the agreement for convenience with the specified notice, and either party may terminate for uncured material breach.
What Was Disclosed
Kura Oncology disclosed the formation of subsidiary Caspian Therapeutics, a $50.0 million Series A preferred stock closing, a Contribution and License Agreement transferring menin inhibitor assets including KO-7246, and an Intercompany Services Agreement, all effective September 8, 2026.




Please wait processing your request...